Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Net Cash Flow: 2019-2024

Historic Net Cash Flow for Day One Biopharmaceuticals (DAWN) over the last 6 years, with Dec 2024 value amounting to -$105.8 million.

  • Day One Biopharmaceuticals' Net Cash Flow fell 95.82% to $7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$379.5 million, marking a year-over-year decrease of 308.99%. This contributed to the annual value of -$105.8 million for FY2024, which is 172.71% down from last year.
  • According to the latest figures from FY2024, Day One Biopharmaceuticals' Net Cash Flow is -$105.8 million, which was down 172.71% from $145.5 million recorded in FY2023.
  • Day One Biopharmaceuticals' 5-year Net Cash Flow high stood at $240.6 million for FY2021, and its period low was -$199.0 million during FY2022.
  • Moreover, its 3-year median value for Net Cash Flow was -$105.8 million (2024), whereas its average is -$53.1 million.
  • Per our database at Business Quant, Day One Biopharmaceuticals' Net Cash Flow skyrocketed by 1,367.32% in 2021 and then slumped by 182.74% in 2022.
  • Over the past 5 years, Day One Biopharmaceuticals' Net Cash Flow (Yearly) stood at $16.4 million in 2020, then soared by 1,367.32% to $240.6 million in 2021, then crashed by 182.74% to -$199.0 million in 2022, then surged by 173.11% to $145.5 million in 2023, then slumped by 172.71% to -$105.8 million in 2024.